Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01520389 · ClinicalTrials.gov registry record · Phase 1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT01520389 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 112 participants.
The verdict
NCT01520389, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
Interventions
- DRUG MM-151
- DRUG MM-151 + irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01520389
The ClinicalTrials.gov registry entry for NCT01520389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MM-151 is the first listed.
NCT01520389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01520389 about?
NCT01520389 is a clinical study titled "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment". This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
What is the current status of trial NCT01520389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2012-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01520389?
The interventions under investigation include: MM-151 (DRUG), MM-151 + irinotecan (DRUG).
Who is sponsoring clinical trial NCT01520389?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.